FDA OKs Abilify For Autism-linked Irritability
PRINCETON, N.J. (AP) ¿ The U.S. Food and Drug Administration has approved top-selling Abilify as a treatment for autism-related irritability in children from the ages of 6 to 17, drug maker Bristol-Myers Squibb Co. said Friday.
Bristol-Myers and Otsuka Pharmaceutical Co., based in Tokyo, are collaborators on the development and distribution of Abilify in the U.S. and Europe.
Abilify is Bristol-Myers' second-biggest revenue generator, with $2.2 billion in 2008 sales.
The FDA's latest approval allows the drug to be used to treat symptoms associated with autism such as aggression toward others, deliberate infliction of self-injury, tempter tantrums and moodiness.The companies said in a statement that it was intended to be used as part of a more comprehensive treatment program that includes educational, psychological and social aspects. Several other drug companies sell medications that compete with Abilify for customers. One is Schering-Plough Corp.'s Saphris, used to treat schizophrenia and bipolar disorder. Others include Pfizer Inc.'s Geodon, Johnson & Johnson's Risperdal, AstraZeneca PLC's Seroquel and Eli Lilly & Co.'s Zyprexa. The drugs have combined sales of well over $15 billion a year. Bristol-Myers shares rose 4 cents to $24.50 in after-hours trading Friday after closing at $24.46, up 43 cents from a day earlier.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV